• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2014 Fiscal Year Final Research Report

Development of a novel antibody therapy based on antibody-dependent cellular cytotoxicity activity against lung cancer and mesothelioma and identification of the immunological biomarkers

Research Project

  • PDF
Project/Area Number 24390210
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypePartial Multi-year Fund
Section一般
Research Field Respiratory organ internal medicine
Research InstitutionThe University of Tokushima

Principal Investigator

NISHIOKA Yasuhiko  徳島大学, ヘルスバイオサイエンス研究部, 教授 (70274199)

Co-Investigator(Kenkyū-buntansha) KATO Yukinari  東北大学, 医学(系)研究科(研究院), 教授 (00571811)
KAKIUCHI Soji  徳島大学, 病院, 講師 (50380100)
GOTO Hisatsugu  徳島大学, 大学院ヘルスバイオサイエンス研究部, 講師 (00437641)
Project Period (FY) 2012-04-01 – 2015-03-31
Keywords抗体療法 / ADCC / ポドプラニン / 肺癌 / 悪性胸膜中皮腫 / 免疫療法 / バイオマーカー
Outline of Final Research Achievements

We developed novel antibodies against podoplanin expressing in lung squamous cell carcinoma and mesothelioma. We generated a human-rat chimeric anti-podoplanin antibody NZ-8 which showed higher anti-tumor activity in mouse xenograft model based on antibody-dependent cellular and complement- dependent cytotoxicity as compared to those of the rat antibody NZ-1. The binding activity of NZ-8 seemed to be higher against podoplanin expressing in tumor cells rather than normal cells such as alveolar cells or podocytes, indicating the advantage for clinical use of NZ-8. We finally developed the chimeric antibody NZ-12 showing the higher anti-tumor activity than NZ-8. Furthermore, gene expression analyses in xenograft tumors treated with NZ-1 identified the candidate genes related with the biological activity of NZ-1/NZ-8.

Free Research Field

医歯薬学

URL: 

Published: 2016-06-03  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi